How myNEO differs in immune target discovery
myNEO helps you from immune-target discovery through design, ranking, and analysis. Use one solution, or combine several into one workflow. What stands out is a wider antigen search and proprietary algorithms for immunogenicity and presentation prediction.
A wider antigen landscape than SNVs and indels
ImmunoEngine uses whole-genome sequencing, so it also captures transposable elements, intronic events, gene fusions, neoisoforms, and camyotope dark-genome targets. That added antigen space is especially relevant for patients with low tumor mutational burden, where SNV and indel discovery often yields too few candidates.
The search uses DNA and RNA sequencing from the tumor, and DNA sequencing from matched healthy tissue. Comparing tumor and healthy DNA identifies alterations that are tumor-specific rather than inherited. Tumor RNA then shows which alterations are expressed.
Methods paper: Godazandeh et al. →Presentation, not only binding
Antigen processing includes cleavage, transport, MHC binding, and surface presentation. Binding predictors capture only one of those steps. neoMS is HLA-agnostic and trained on mass-spectrometry MHC ligandomic data, so ranking reflects peptides that actually reach the cell surface. It covers MHC class I and class II.
Mill et al., bioRxiv 2022 →T-cell immunogenicity prediction
neoIM estimates the probability that an epitope elicits a T-cell response. Candidates are ranked by predicted CD8+ and CD4+ T-cell immunogenicity. In published retrospective analyses, neoIM achieved up to 30% higher precision than existing predictors and identified up to 50% more clinically actionable neoantigens.
Pfitzer et al., Vaccines 2025 →Shared targets from the dark genome
Camyotopes are proprietary tumor antigens from translated dark-genome regions. They expand the shared target space for off-the-shelf immunotherapies beyond recurrent coding mutations, with broader population coverage and more targets per patient than conventional shared antigens.
Independent modules, not a locked pipeline
Each solution can be used independently for a defined task or project, or multiple solutions can be combined into an integrated workflow. Live hosted applications today are myADA, mySURFACE, and neoHUB.
Solutions →Partnered and internal programs
myNEO technology is used in a Phase I personalized DNA program with the University of Liverpool for patients with non-small cell lung cancer. Two additional personalized programs are at the preclinical stage with undisclosed European and US partners targeting solid tumors.
As of August 2026, the lead internal program is MNE-C261, an off-the-shelf mRNA vaccine targeting camyotopes in microsatellite-stable colorectal cancer. The program is in preclinical development, with clinical initiation targeted for Q4 2027.
Pipeline and assets →Published methods behind these claims
Each ranking claim on this page points to a paper or whitepaper already listed on the publications page. Reviews in Trends in Cancer and Cancer Cell cover the broader neoantigen field.
Talk to our team
Discuss ImmunoEngine, neoMS, neoIM, or a dedicated solution for your program.